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Conclusions: This original radiotherapy regimen delivering only a 
single stereotactic dose per week seems to be highly feasible with an 
interesting high rate of efficacy for patients with oligometastases 
from different solid tumors. Overall, the once weekly treatment is 
very compliant in advanced cancer stage especially for elderly and 
frail patients. 
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Purpose/Objective: To retrospectively evaluate external beam re-
irradiation (re-EBRT), delivered to the prostate or prostatic bed for 
local recurrence after radical or post-operative/salvage radiotherapy. 
Materials and Methods: 17 pts have been treated with re-EBRT at our 
Department between 2/2008 and 8/2012. Previously RT included 
radical RT 13 pts (12 pts with EBRT and 1 pt with brachytherapy, post-
operative RT (2 pts) or salvage RT (1 pt), 1 pt not reported. All pts 
had local relapse in the prostate or prostatic bed with no distant 
metastasis: biopsy was performed in all but 1 pts, and all the pts had 
total body computer tomography (CT) or 11C-choline positron emission 
tomography scan. One pt. was previously treated also with 3D-CRT for 
lymph node recurrence with complete remission.  
The mean age, iPSA and Gleason Score (GS) at diagnosis were 61 yrs 
(49-67), 15 ng/ml (4.57-67) and 6 (4-9), respectively.  
The re-EBRT technique included 3D IGRT, stereotactic RT, IMRT, 
stereotactic RT + IMRT, CyberKnife respectively in 1,8,6,1,1 pts. The 
following schedules were employed: 25 Gy/5 fr(12 pts), 30 Gy/6 fr(4 
pts) and 15 Gy/3 fr (1 pt). Four pts were included in a previous study.  
Concomitant hormonal therapy (HT) was administered in 7 pts. 
Toxicity and tumor response were evaluated using Radiation Therapy 
Oncology Group/European Organization for Research and Treatment 
of Cancer and Response Evaluation Criteria In Solid Tumors criteria. 
Biochemical and clinical response, using radiologic criteria, was also 
registered.  
Results: Acute toxicity included: 3 G1, 1 G2 genitourinary events; 1 
G1, 1 G2 gastrointestinal events. Late toxicities (> 6 months of f.u., 
data available in 9 pts): 5 pts with no toxicity; 2 G1 gastrointestinal 
and 1 G1 genitourinary events respectively.  
The mean interval between the primary treatment and the clinical 
local relapse was 64 months, and the mean follow-up after re-EBRT 
was 24 months (5-30). Two pts died for the prostate cancer 
progression at distant sites: the interval between re-EBRT and the 
death was 30 mo. for each. The remaining 15 patients are alive: 12 
with no evidence of disease and 3 pt is alive with disease in clinical 
control with HT. 
Conclusions: In our single institution preliminary experience re-EBRT 
of local relapse of the prostate cancer appears feasible and well 
tolerated. Local control was excellent (non local recurrence was 
registered within mean follow-up of 2 years) and 70% of patients alive 
with non evidence of disease. Longer follow-up and bigger patient 
series is warranted in order to confirm these promising early findings.  
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Purpose/Objective: While research in the physics domain for 
Flattening Filter Free Beams (FFF) beams is increasing, there are few 
clinical data of FFF beams in clinical practice. Here we reported early 
clinical results of SBRT and FFF delivery in isolated lymph node 
oligometastatic patients. 
Materials and Methods: Between October 2010 and March 2012, 34 
patients were treated with SBRT for oligometastatic lymph node 
metastasis using Volumetric Modulated Arc Therapy (RapidArc on 
Truebeam platform). We retrospectively evaluated a total of 25 
patients for isolated lymph node metastases in abdomen and/or pelvis 
treated with SBRT and FFF (28 treatments). Prescription doses were 
45 Gy in 6 consecutive fractions of 7.5 Gy for all 28 treatments. The 
inclusion criteria were: age≥18years, WHO performance status ≤ 2, 
histologically-proven of primary cancer disease, M1 stage with primary 
cancer site radically treated with complete response/resection or 
stable, no other site of disease in progression (amaximum of 3 lymph 
node sites of disease to treat), diameter of lymph node Target less 
than 5 cm, Abdomen/pelvic site, no previous surgery or RT in the 
region to treat, obtained informed consent. Chemotherapy, when 
prescribed, was interrupted from 20 days before the simulation to the 
first evaluation after the end of SBRT treatment, as scheduled. Acute 
toxicity was recorded and scored according to CTCAE v.4. Local 
control evaluation was scored by means of CT scan and/or PET scan, 
according to PERCIST criteria. 
Results: All 25 FFF SBRT patients completed the treatment. Acute 
gastrointestinal toxicity was minimal: one patient showed Grade 1 
gastrointestinal toxicity.Three other patients presented Grade 2 
toxicity. No Grade 3 or higher was recorded. All toxicities were 
recovered within one week. The preliminary clinical results at the 
median follow up of 195 days are: complete response in 12 cases, 
partial response in 11, stable disease in 5, with an overall response 
rate of 82%; no local progression was recorded.  
Conclusions: Data of acute toxicity are excellent for patients treated 
with SBRT with VMAT using FFF beams. Preliminary clinical results 
showed a high rate of local control in irradiated lesion. Further data 
and longer follow up are needed to assess late toxicity and definitive 
clinical outcomes. 
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Purpose/Objective: Cancer-Associated Fibroblasts (CAFs) are major 
components of solid malignancies and play central roles on cancer 
sustainability. In the context of radiotherapy, collateral effects of 
ablative ionizing radiation (AIR) on stromal components of tumors 
remain understudied. In this work we have examined the impact of 
AIR on CAFs from human lung tumors.  
Materials and Methods: CAFs prepared from resected human lung 
tumors were exposed to AIR (1x18Gy). Intrinsic radio-sensitivity was 
evaluated by checking viability and extent of DNA-damage responses 
at scalating radiation doses. Proliferation, migration and invasion 
rates were monitored in label-free assays by xCELLigence system. 
Inflammatory mediators, as well as regulators of angiogenesis and 
tumor growth were analyzed by multiplex protein assasy in 
conditioned medium (CM) from irradiated and control CAFs. 
Additionally the entire secretory protein profile was examined by 
mass spectometry. In functional assasys, the potential effects of CAFs 
released factors on the proliferative and migratory capacity of lung 
tumor cell (H520 and H522) and on endothelial cells (HUVEC) was also 
investigated. 
Results: Our results show that CAFs survive ablative doses of 
radiation, but cells enter a senescent state associated with reduced 
proliferation and invasion. A lowered MMP-1 expression and the 
stabilization of focal contacts via integrins were responsable 
mechanisms behind the reduced cell motility. On the other hand, 
analyses of the secretory profile revealed a reduced expression of 
angiogenic factors like SDF-1a and TSP-2, and altered expression of 
tumor regulators such as bFGF, PEDF and MIF upon radiation. No 
prominensignificant differences were observed on the behaviour of 
tumor cells or endothelial cells exposed to irradiated and control CAF-
CM 
Conclusions: AIR provoked a reduction in the proliferative and 
migratory abilities of CAFs, along with a transformation of their 
secretory profile. These radiation-induced chages on tumor resident 
fibroblasts could influence the behaviour of adjacent cells in the 
tumor tissue and hence influence therapeutic outcomes. Downstream 
consequences of the changes observed in this study merits further 
investigations.  
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Purpose/Objective: Stereotactic radiotherapy (SRT) of brain 
metastasis can lead to lesion growth after varying time intervals. The 
pathophysiology of this radiation effect, that has to be distinguished 
from regrowth of the tumor, is not well understood. We made cine-
loops of serial MRI scans of patients with this effect in order to 
describe the evolution of SRT associated changes. 
Materials and Methods: Ten patients who had received SRT of brain 
metastases were selected from our departmental database. They had 
been treated on a Novalis (Brainlab, Feldkirchen, Germany). Patients 
received either single doses of 21Gy or 18Gy or three doses of 8Gy. 
Selection criteria for this study were: lesion growth after SRT not 
caused by tumor progression and the availability of at least five three-
monthly follow-up MRI scans. For the cine-loops we used post-
gadolinium 3D T1 weighted images. These MRI scans were co-
registered using iPlan 4.5 (Brainlab). From the pre-SRT MRI the axial 
slice with the largest lesion diameter was selected. For the cine-loop 
we copied the corresponding follow-up MRI images into Microsoft 
Windows Movie Maker (Microsoft Corp. Redmond USA), put them in 
chronological order and used the fading mode for the transitions 
between the separate slices. The ten MRI cine loops were interpreted 
in a joint meeting of the authors. 
Results: In all patients the cine-loops were found to be superior to the 
separate MRI’s for describing and interpreting the events after SRT. 
The sequence of events showed a similar pattern in all patients, but 
the timing of the observed events varied. In the movies we saw partial 
or complete regression of the metastasis first, followed by an 
enlarging area of contrast enhancement in the surrounding brain 
tissue. In five patients the volume of this enhancement eventually 
decreased. Histological examination of the enhancing tissue was 
possible in two patients and confirmed the existence of radiation 
necrosis without residual tumor. 
Conclusions: Cine-loop MRI analysis enabled better understanding of 
the changes that develop in follow-up MRI scans after SRT of brain 
metastases. The cine-loops showed a typical growth pattern after SRT 
with a gradually expanding area of contrast enhancement in the brain 
tissue surrounding the shrinking metastasis. 
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Purpose/Objective: To analyze the toxicity of hypofractionated lung 
SBRT according to QUANTEC recommendations.  
Materials and Methods: From 2002 to 2010, 44 (25 male, 19 female) 
patients with small primary lung cancer or oligometastasis were 
treated with several hypo-fractionation schemes of SBRT at our 
institution. All patients were immobilized using a stereotactic body 
frame, simulated with CT scan and treated with multiple static 6 MV 
beams. A total of 48 lesions were treated, among which 2 patients had 
2 lesions and 1 patient had 3 lesions. The median follow-up was 12 
months. We exported the composite dose volume histograms (DVHs) of 
gross target volume (GTV), planning target volume (PTV) and normal 
lung tissue (whole lung-GTV). For each patient, normal tissue 
complication probability (NTCP) based on the Poisson model was 
calculated using the normal lung DVH, and normalized total dose 
(NTD) volume histograms were generated at 2Gy fractions with a/b = 
3.7 Gy to account for different fractionations. Mean dose and V20 
(%volume receiving 20Gy) of GTV, PTV and normal lung derived from 
DVH/NTDVH were correlated with clinical follow-up. Variable 
importance for projection (VIP) and correlation coefficient (R) were 
calculated for each variable using partial least squares regression 
(PLSR) and logistic regression (LR) to identify the prediction factors 
for normal tissue complications. 
Results: There were 2 (4.2%) local failures, 4 (9.1%) grade 2 
pneumonitis and 3 (6.8%) radiation-induced fibrosis. The <10% 
pneumonitis rate is in line with the QUANTEC report for lung SBRT. 
5/14 (35.7%) of the lesions in right lower lobe developed 
complications, in comparison to 1/16 (6.3%) in right upper and middle 
lobes, 0/5 (0%) in left lower lobe and 1/11 (9.1%) in left upper lobe. 
The most influential VIP for predicting the complications were mean 
GTV dose (VIP =1.500, R=0.145) and GTV volume (VIP=1.451, R=-
0.140), followed by NTCP (VIP=1.106,R=0.107) although the calculated 
probability was much higher than the frequency of complications. LR 
was able to produce a reasonable NTCP curve for these three 
variables. The prediction factors used for conventional lung RT 
complications, i.e., V20, VNTD20, mean dose and mean NTD of normal 
lung had only moderate or low VIP (<0.894), were negatively 
correlated (R between -0.044 and -0.086) and could not be fit to a 
NTCP logistic curve.
Conclusions: Radiation induced complication for SBRT increases with 
the mean GTV dose and cannot be predicted with the known 
prediction factors for conventional lung RT. The cause for higher 
probability of complications for right lower lobe is unclear and needs 
further investigations. NTCP based on Poisson model might be applied 
to lung SBRT but requires different modeling parameters than that 
used for conventional lung RT. 
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Purpose/Objective: To evaluate the feasibility and efficacy of 
Stereotactic body radiation therapy (SBRT) for primary liver lesions 
and liver metastases treated with linear accelerators. 
Materials and Methods: Patients with either hepatocellular 
carcinoma, cholangiocarcinoma or metastatic liver lesions who had 
one to three lesions treated with SBRT in a single institution were 
retrospectively reviewed. Tumor response was evaluated according to 
EASL criteria 3 months after SBRT completion using MRI and/or 
abdominal CT scan. Responses were categorised as: Stable Disease 
(SD), Partial Response (PR),Complete Response (CR), Local Progression 
or Distant Progression in cases of new intra-hepatic lesions out-of-
field or extra-hepatic metastases. Local Control (LC), Progression Free 
Survival (PFS), Overall Survival (OS) and treatment-related toxicities 
are reported. 
Results: Between 2007 and 2012, 20 patients with a total of 24 lesions 
were treated with SBRT. Fourteen patients presented hepatocellular 
carcinoma (HCC), the others had either metastatic lesions from 
colorectal cancer (CRC) or cholangiocarcinoma. The median diameter 
of the lesions was 23 mm (5-98). The dose per fraction ranged from 6 
to 20 Gy with a median total dose of 60 Gy (range: 36-60 Gy). The 
dose was prescribed to the 80% isodose line covering the PTV. The 
median follow-up was 24 months. The actuarial LC rate was 78% for 
patients with HCC and 83% for those with adenocarcinoma and 
cholangiocarcinoma. Median OS was 37 months and OS rates were 88% 
at 12 and 24months. PFS was 65% and 53% at 6 and 24 months, 
respectively. Acute grade 3-4 toxicities occurred in 2 patients; a small 
proportion of the other patients experienced grade 1 or 2 toxicities. 
Conclusions: SBRT provides excellent local control with minimal side 
effects in selected patients.  
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Purpose/Objective: Describe Stereotactic Body RadioTherapy (SBRT) 
technique for treatment of this disease presentation 
Review Outcomes (Local Control, Overall Survival, and Toxicity) 
Materials and Methods: A total of 12 patients were treated with SBRT 
by the CyberKnife system between August 2009 and July 2012. All 
patients had initially presented with local/loco-regional disease. Six 
patients recurred with sternal metastases, six with Internal Mammary 
Chain (IMC) lymph node metastases. The Baseline Clinical 
Characteristics of the patients were well matched with respect to 
Age, Grade, Stage and Receptor Status at presentation. Median age at 
presentation was 45 years (Range= 30-63 years). Median Disease-Free 
Interval between presentation and relapse was 3 years (Range 1-38 
years). 2 patients that recurred in the Sternum had synchronous 
distant disease. 7 patients (58%) of the group as a whole were given 
Chemotherapy as the first treatment at the time of Sternal/IMC node 
recurrence. 10 patients (83%) had received prior conventional 
radiotherapy which overlapped with the target site.Median CTV-PTV 
